ATE533771T1 - Cyclopropylkondensierte indolobenzazepine als hcv-ns5b-inhibitoren - Google Patents
Cyclopropylkondensierte indolobenzazepine als hcv-ns5b-inhibitorenInfo
- Publication number
- ATE533771T1 ATE533771T1 AT07874300T AT07874300T ATE533771T1 AT E533771 T1 ATE533771 T1 AT E533771T1 AT 07874300 T AT07874300 T AT 07874300T AT 07874300 T AT07874300 T AT 07874300T AT E533771 T1 ATE533771 T1 AT E533771T1
- Authority
- AT
- Austria
- Prior art keywords
- hcv
- indolobenzazepines
- cyclopropyl
- condensed
- ns5b inhibitors
- Prior art date
Links
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 241000711549 Hepacivirus C Species 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2007/085183 WO2009067108A1 (en) | 2007-11-20 | 2007-11-20 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE533771T1 true ATE533771T1 (de) | 2011-12-15 |
Family
ID=40010653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07874300T ATE533771T1 (de) | 2007-11-20 | 2007-11-20 | Cyclopropylkondensierte indolobenzazepine als hcv-ns5b-inhibitoren |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2209789B1 (de) |
| JP (1) | JP5416710B2 (de) |
| KR (1) | KR20100108341A (de) |
| CN (1) | CN101918410B (de) |
| AT (1) | ATE533771T1 (de) |
| AU (1) | AU2007361468A1 (de) |
| CY (1) | CY1112699T1 (de) |
| DK (1) | DK2209789T3 (de) |
| ES (1) | ES2375065T3 (de) |
| MX (1) | MX2010005226A (de) |
| PL (1) | PL2209789T3 (de) |
| PT (1) | PT2209789E (de) |
| SI (1) | SI2209789T1 (de) |
| WO (1) | WO2009067108A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| MX2010010061A (es) | 2008-03-27 | 2010-09-30 | Bristol Myers Squibb Co | Compuestos para el tratamiento de hepatitis c. |
| JP2011515484A (ja) | 2008-03-27 | 2011-05-19 | ブリストル−マイヤーズ スクイブ カンパニー | ピロリジン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤 |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
| WO2012092411A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc. | Phenanthridine macrocyclic hepatitis c serine protease inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| CA2879398A1 (en) * | 2012-07-18 | 2014-01-23 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| US10874746B2 (en) * | 2016-02-08 | 2020-12-29 | Synaffix B.V. | Sulfamide linkers for use in bioconjugates |
| EP3413915A1 (de) | 2016-02-08 | 2018-12-19 | Synaffix B.V. | Antikörperkonjugate mit verbessertem therapeutischem index zur abzielung auf her2-tumoren und verfahren zur verbesserung des therapeutischen index von antikörperkonjugaten |
| US11951175B2 (en) | 2016-02-08 | 2024-04-09 | Synaffix B.V. | Bioconjugates containing sulfamide linkers for use in treatment |
| EP3429355B1 (de) | 2016-03-15 | 2020-02-05 | Bayer CropScience AG | Substituierte sulfonylamide zur bekämpfung tierischer schädlinge |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| KR20220098170A (ko) | 2019-11-07 | 2022-07-11 | 바이엘 악티엔게젤샤프트 | 동물 해충 방제를 위한 치환된 술포닐 아미드 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100387580C (zh) * | 1997-09-29 | 2008-05-14 | 明治制果株式会社 | 三环三唑并苯并氮杂䓬衍生物、用于制备该衍生物的方法和抗变态反应剂 |
| US7399758B2 (en) * | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) * | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| ES2343914T3 (es) * | 2006-05-25 | 2010-08-12 | Bristol-Myers Squibb Company | Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo. |
| CA2672250C (en) * | 2006-12-20 | 2013-04-30 | Ian Stansfield | Antiviral indoles |
| US7541351B2 (en) * | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| EP2121694B1 (de) * | 2007-03-13 | 2014-07-16 | Bristol-Myers Squibb Company | Cyclopropyl kondensierte indolobenzazepine als hcv-ns5b-inhibitoren |
| US7547690B2 (en) * | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7541353B2 (en) * | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7538102B2 (en) * | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7521444B2 (en) * | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
-
2007
- 2007-11-20 AU AU2007361468A patent/AU2007361468A1/en not_active Abandoned
- 2007-11-20 PT PT07874300T patent/PT2209789E/pt unknown
- 2007-11-20 AT AT07874300T patent/ATE533771T1/de active
- 2007-11-20 MX MX2010005226A patent/MX2010005226A/es active IP Right Grant
- 2007-11-20 DK DK07874300.2T patent/DK2209789T3/da active
- 2007-11-20 ES ES07874300T patent/ES2375065T3/es active Active
- 2007-11-20 KR KR1020107013455A patent/KR20100108341A/ko not_active Ceased
- 2007-11-20 PL PL07874300T patent/PL2209789T3/pl unknown
- 2007-11-20 CN CN2007801022148A patent/CN101918410B/zh not_active Expired - Fee Related
- 2007-11-20 EP EP07874300A patent/EP2209789B1/de not_active Not-in-force
- 2007-11-20 WO PCT/US2007/085183 patent/WO2009067108A1/en not_active Ceased
- 2007-11-20 JP JP2010534924A patent/JP5416710B2/ja not_active Expired - Fee Related
- 2007-11-20 SI SI200730855T patent/SI2209789T1/sl unknown
-
2012
- 2012-02-14 CY CY20121100152T patent/CY1112699T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007361468A1 (en) | 2009-05-28 |
| JP2011503229A (ja) | 2011-01-27 |
| ES2375065T3 (es) | 2012-02-24 |
| CY1112699T1 (el) | 2016-02-10 |
| CN101918410A (zh) | 2010-12-15 |
| CN101918410B (zh) | 2013-02-27 |
| PT2209789E (pt) | 2012-01-16 |
| MX2010005226A (es) | 2010-05-27 |
| JP5416710B2 (ja) | 2014-02-12 |
| WO2009067108A1 (en) | 2009-05-28 |
| EP2209789B1 (de) | 2011-11-16 |
| KR20100108341A (ko) | 2010-10-06 |
| DK2209789T3 (da) | 2012-03-05 |
| SI2209789T1 (sl) | 2012-06-29 |
| PL2209789T3 (pl) | 2012-04-30 |
| EP2209789A1 (de) | 2010-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE469155T1 (de) | Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer | |
| DK1987038T3 (da) | HCV NS5B-hæmmere | |
| DK2209789T3 (da) | Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere | |
| ATE522532T1 (de) | Verbindungen zur behandlung von hepatitis c | |
| TW200745120A (en) | Indolobenzazepine HCV NS5B inhibitors | |
| ATE494291T1 (de) | Verbindungen zur behandlung von hepatitis c | |
| CO6190510A2 (es) | Inhibidores del virus de la hepatitis c | |
| EA200802346A1 (ru) | Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с | |
| MX2010001416A (es) | Compuesto para el tratamiento de la hepatitis c. | |
| WO2007140200A3 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
| CY1113752T1 (el) | Μακροκυκλικες ενωσεις κινοξαλινης ως αναστολεις πρωτεασεις ns3 του hcv | |
| EA201071315A1 (ru) | Ингибиторы протеазы вируса гепатита с | |
| EA200900676A1 (ru) | Ингибиторы вируса гепатита с | |
| ATE551343T1 (de) | Tetracyclische verbindungen zur behandlung von hepatitis c | |
| EA201000948A1 (ru) | Ингибиторы вирусной полимеразы | |
| NO20090453L (no) | Hepatitt C Virusinhibitorer | |
| EA200901101A1 (ru) | Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс | |
| NO20091845L (no) | Macrocykliske peptider som hepatitt C virus-inhibitorer | |
| EA200901241A1 (ru) | Соединения для лечения гепатита с | |
| NO20091846L (no) | Makrocykliske peptider som hepatitt C virus- inhibitorer | |
| ATE505473T1 (de) | Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c | |
| TW200745035A (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| MX2010010061A (es) | Compuestos para el tratamiento de hepatitis c. | |
| ATE531373T1 (de) | Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren |